AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00928291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: procalcitonin
Description: plasma PCT measurement
Study NCT00928291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: procalcitonin
Description: plasma PCT measurement
Study NCT00928291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic therapy
Description: antibiotic therapy use
Study NCT00928291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic therapy
Description: antibiotic therapy use
Study NCT04384003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shear Wave Ultrasound Elastography
Description: Scanned protocols of sonographic imaging will be used in this study to measure extrinsic (FDL, FHL and PER) and intrinsic (AbdH, FDB and FHB) muscle CSA and thickness, and plantar fascia thickness (at heel, mid and forefoot sites).~The muscle stiffness will be calculated from the program provided by the US machine as shown real time elastography (RTE, unit: KPa).
Study NCT01204775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin IR
Description: Tablets, Oral, 500 mg, Once Daily, 17-52 weeks
Study NCT01204775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Metformin)
Description: Tablets, Oral, Once daily, 1-16 weeks
Study NCT01204775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin (Active Rescue)
Description: Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks
Study NCT01204775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (Active Rescue)
Description: Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks
Study NCT01668992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family intervention
Description: 12-week parenting skills program for Burmese migrant and displaced children and families.
Study NCT00276016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Description: immediate-release 12 mg capsules for oral administration
Study NCT00276016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine
Description: 60 mg immediate-release tablets for oral administration
Study NCT00276016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsules
Study NCT02854774 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle activation exercises
Description: Activation of either muscles activating the knee or hip.
Study NCT04384003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The 3-D Motion Analysis
Description: The 3-D Motion Analysis, Forceplates and EMG acquisition system and full body kinematic model (Bonita, VICON Corp, UK) in the Biomechanics and Motor Control Laboratory (BMCL).
Study NCT04384003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromyographic
Description: Electromyographic activity (EMG) of AbdH, TA, PL, SO, gluteus medius (Glut Med) and gluteus maximus (Glut Max) will be recorded bilaterally using pairs of surface electrodes. Motor coordination of these muscles will be evaluated through assessment of temporal and spatial parameters of EMG during functional tasks such as kicking in one leg standing. The primary outcome measure will be percentage of EMG relative to maximal voluntary contraction (MVC) on the same side. In order to remove the potential for investigator bias, all data will be presented individually without identification of the muscle, order of trials or whether the trials precede or follow the intervention.
Study NCT03435874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 RH5
Description: Vaccine
Study NCT04384003 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Foot intrinsic muscle assessment and training device
Description: The main concept for this design is to provide the quantitative assessment of the foot intrinsic muscles and facilitation of intrinsic muscles of the fool during functional sporting activities such single-leg-standing.
Study NCT03435874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA RH5
Description: Vaccine
Study NCT03435874 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies Vaccine
Description: Vaccine
Study NCT02345148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 84 mg will be self-administered by participants as intranasal spray at 0, 5 and 10 minutes on Day 1.
Study NCT01822639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2944404 FDC
Description: Uncoated, round, yellow white bilayer fixed dose combination tablet containing 5 mg amlodipine and 20 mg enalapril for single dose oral administration in each period.
Study NCT01822639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Description: Emerald-shaped white 5 mg amlodipine table for single dose oral co-administration with enalapril maleate tablet in each period.
Study NCT01822639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Maleate 20 mg
Description: Peach triangle shaped 20 mg enalapril maleate tablet for single dose oral co-administration with amlodipine in each period.
Study NCT01686464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone and valacyclovir treatments
Description: patients were administered prednisone as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking valacyclovir 400 mg in three doses daily for 10 days.
Study NCT01686464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic and Oxygen Treatment
Description: MOMC treatment was given as daily 20 min section for 10 days with 2\~3 days of intermission between. Oxygen therapy was given simultaneously at a flow rate of 2\~3.0 L / min for the same duration during all acupuncture sections.
Study NCT03778892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'Project Raincoat' Mobile Phone Application
Description: Mobile phone application with weekly input channels for PrEP use, condom use, number of sex partners and sex acts and a calculation of self-HIV risk feedback scoring. Scoring system for attendance of visits, normal blood tests and use of application. Points redeemable for cash. Optional alarm system to remind to take medications and attend visits.
Study NCT03561714 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cardometabolic Team Intervention
Description: The CMC-TI team included a registered nurse/certified diabetes educator (RN/CDE) Care Manager, medical assistant (MA) Health Coach, and RN Depression Care Manager. Decision support tools guided therapy for glucose, BP, low-density lipoprotein cholesterol (LDL-c), and depression. At the intervention clinic, the 12-month CMC-TI was delivered to all qualifying patients; surveys were administered to evaluate relevant patient-reported outcomes over 12 months.
Study NCT03063060 — intervention group
Intervention type: OTHER
Intervention: vitamin D levels and Calcium levels examination
Description: observational
Study NCT03779230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
Study NCT04408729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP My Way
Description: Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, and 6 via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 6 and as needed (e.g., treatment for positive tests).~This intervention aims to increase adherence/persistence on PrEP. We hypothesize that removing the structural barriers and stigma associated with going to the clinic, women may be more likely to continue on PrEP.
Study NCT00656825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P144 cream
Description: P144 cream will be given at a dose of 100 μg/mL
Study NCT00656825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P144 cream
Description: P144 cream will be given at a dose of 200 μg/mL
Study NCT00656825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P144 cream
Description: P144 cream will be given at a dose of 300 μg/mL
Study NCT00656825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be randomly given to 4 subjects in each panel
Study NCT02734966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Isoglycyrrhizinate Injection 100mg OD
Description: Magnesium Isoglycyrrhizinate Injection 100mg OD
Study NCT02734966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Isoglycyrrhizinate Injection 200mg OD
Description: Magnesium Isoglycyrrhizinate Injection 200mg OD for 4 weeks
Study NCT02734966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiopronin Injection
Description: Tiopronin Injection 200mg OD
Study NCT02737488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Systems Therapy (TST)
Description: Treatment will be delivered by clinicians and trainees working at the CSC who have been trained in delivering TST. Participants who begin treatment in the safety-focused phase will have their treatment sessions in their homes. Whenever a child enters a different phase of treatment, he or she will go to the site for office visits. At the beginning of treatment, TST clinicians will do a brief diagnostic assessment. All documentation that is completed by the clinician as part of TST treatment at the NYU Langone Medical Center will be documented using Epic, a standard of care integrated health information system for patient safety. Although we are not providing the CSC's standard of care in this study,we are replicating standard care as TST is standard care in other settings. Providing medication is part of standard TST treatment and conforms to good usual practice integrated with psychotherapy. Medication will not be prescribed for research purposes.
Study NCT02737488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Youth in the control group will be referred to a mental health clinic in close proximity to their residence, in order to receive an evaluation and trauma treatment as usually provided. It cannot be specifically determined, in advance, the nature of this treatment.~The clinics will be contacted after the family enrolls to determine if there was a specific protocol followed. An NYU CSC research coordinator will contact the clinic and assist in scheduling the subject's first visit. Families who do not enroll in any community treatment or dropout of treatment will be followed according to the research protocol for data collection. At the 3, 6, and 9 month assessments, the research coordinator will request the patient's records from the community treatment clinic they are attending in order to track and keep record of the youth's treatment modality, progress, and visit frequency.
Study NCT01762644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Cyclosporine and Oral Omeprazole
Study NCT01762644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Omeprazole
Study NCT01994408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: default intensification
Description: The investigators will determine which blood pressure medications to use. No specific drug will be tested but rather the automatic intensification of medications is the intervention. Examples of drugs used in this study are calcium channel blockers (e.g., amlodipine 2.5 mg to 10 mg) or ACE-inhibitors (e.g., lisinopril 5 mg to 40 mg) or diuretics (HCTZ 25 mg).
Study NCT00473317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Exposure
Description: Each subject will wear a swimming suit and be exposed to sunlight for 30 minutes total (15 minutes lying on back, 15 minutes lying on stomach).
Study NCT00760916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C 1 mg
Description: UT-15C 1 mg
Study NCT00760916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C 0.25 mg
Description: UT-15C 0.25 mg
Study NCT00760916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C 5 mg
Description: UT-15C 5 mg
Study NCT00760916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04311333 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endostomal three-dimensional ultrasonography
Description: Examination with rectal probe enclosed by water-filled balloon. Rectal mode. Dynamic examination in different positions with and without increased intra-abdominal pressure.
Study NCT04311333 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computerized tomography of the abdomen
Description: Supine position, without increased intra-abdominal pressure. Experienced radiologist interprets the examination.~If adequate examination has already been performed within the last 10 months, these images will be used and the patient will thus not undergo computerized tomography within the study.
Study NCT04311333 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: Patients will be clinically examined with inspection and palpation in supine and erect position with and without increased intra-abdominal pressure.
Study NCT04311333 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation at laparotomy/laparoscopy
Description: During laparotomy or laparoscopy, inspection and/or palpation of the stoma at the abdominal wall orifice is performed.
Study NCT05696990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3/7 Resistance Training Method
Description: 3/7 Resistance Training Method
Study NCT05696990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3X9 Resistance Training Method
Description: 3X9 Resistance Training Method
Study NCT03992963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid without frequency lowering enabled
Description: Each participant will be fitted with frequency lowering disabled. Disabled means standard hearing loss compensation without lowering higher frequencies in lower frequency areas. The input frequency is mapped to the same frequency in output.
Study NCT03992963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with frequency lowering enabled
Description: Each participant will be fitted with frequency lowering enabled. The principle of the frequency lowering algorithm is to lower high frequencies to a lower frequency region with the aim of ensuring high frequency audibility to improve auditory emotion recognition.
Study NCT04132323 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy according to the randomization group
Study NCT00770783 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thymatron
Description: Right unilateral placement, 3x seizure threshold, 3 times per week for 4 weeks
Study NCT00770783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tonica MagPro MST
Description: 100% power, vertex placement, 3 times per week for 4 weeks
Study NCT04830969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate oral rinse
Description: Paroex® is a non-alcohol chlorhexidine preparation. Participants are to use 15 mL morning and evening for 3 months. With use of chlorhexidine, there is risk of reversible staining of teeth and the possibility of some alteration in taste. There is increased likeliness of staining in smokers, coffee drinkers and those who are susceptible to teeth staining in general. The cleaning of the front teeth is provided at the 3-month visit and helps to reduce any staining that may occur. If there is any alteration in taste, it should go away when use of chlorhexidine stops.
Study NCT04830969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling & Root Planing
Description: SRP is standard treatment of periodontitis. It involves using a scaler to remover subgingival plaque and other debris in the space between teeth and gums.
Study NCT04830969 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling & Root Planing
Description: SRP is standard treatment of periodontitis. It involves using a scaler to remover subgingival plaque and other debris in the space between teeth and gums.
Study NCT04830969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Picks
Description: Soft Picks are a rubber interdental bristle cleaner. Participants are to use Soft Picks morning and evening for all 12 months of the study. They may cause some bleeding of the gums at first usage, but the bleeding should lessen and stop as use is continued (as gums heal). Soft-Picks are a readily available consumer product sold in supermarkets and drug stores.
Study NCT00841386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin-5-phosphate
Description: Riboflavin 0.1% (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) will be applied to the cornea every 2-3 minutes for 15 minutes prior to starting UV irradiation. The UV irradiation will be given in six 5 minute intervals. Additional riboflavin will be administered following each 5 minute UV treatment.
Study NCT00841386 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham cross-linking
Description: Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and 2% methylcellulose solution with 1% sodium fluorescein will be applied to the cornea every 5 minutes for 15 minutes, and then every 5 minutes during the sham UV treatment. The patient will be placed under the UV device, and the aiming beam applied.
Study NCT04725162 — intervention group
Intervention type: RADIATION
Intervention: 18F-FDG
Description: All subjects received 18F-FDG PET examination.
Study NCT04116840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1002 for injection
Description: Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.
Study NCT02386267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-leucine
Description: L-leucine pills per os for 6 months
Study NCT00636519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulism Antitoxin Bivalent (Equine) Types A and B
Description: One vial of Botulism Antitoxin Bivalent(Equine) Types A and B (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage A
Study NCT00636519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulism Antitoxin Heptavalent (Equine) Types A-G
Description: One vial of Heptavalent Botulism Antitoxin (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage B
Study NCT04501237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bruxers with sleep hygiene instructions
Description: the test group will receive instructions of sleep hygiene, limited use of screens and a relaxation audio.
Study NCT01657721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training Program
Description: The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
Study NCT03743597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOCKNLEG
Description: Innovative multilayer leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition understocking (polyamide, cotton, spandex), overstocking (polyamide, spandex)~In each participant all examinations will be performed with both study stockings, one after the other
Study NCT03743597 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOCKNLEG
Description: Innovative multilayer leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition understocking (polyamide, cotton, spandex), overstocking (polyamide, spandex)~In each participant all examinations will be performed with both study stockings, one after the other
Study NCT03743597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sigvaris COTTON
Description: Standard single leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition one stocking (polyamide, spandex, cotton)~In each participant all examinations will be performed with both study stockings, one after the other